Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q37708936)
Watch
English
Molecular pathways: molecular basis for sensitivity and resistance to JAK kinase inhibitors.
scientific article published on 28 February 2014
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
Europe PubMed Central
PMCID
3990645
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24583800%20AND%20SRC:MED&resulttype=core&format=json
retrieved
9 March 2020
review article
1 reference
stated in
Europe PubMed Central
title
Molecular pathways: molecular basis for sensitivity and resistance to JAK kinase inhibitors
(English)
1 reference
stated in
Europe PubMed Central
PMCID
3990645
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24583800%20AND%20SRC:MED&resulttype=core&format=json
retrieved
9 March 2020
author
Sara C Meyer
series ordinal
1
1 reference
stated in
Europe PubMed Central
PMCID
3990645
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24583800%20AND%20SRC:MED&resulttype=core&format=json
retrieved
9 March 2020
author name string
Ross L Levine
series ordinal
2
1 reference
stated in
Europe PubMed Central
PMCID
3990645
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24583800%20AND%20SRC:MED&resulttype=core&format=json
retrieved
9 March 2020
language of work or name
English
0 references
publication date
28 February 2014
1 reference
stated in
Europe PubMed Central
PMCID
3990645
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24583800%20AND%20SRC:MED&resulttype=core&format=json
retrieved
9 March 2020
published in
Clinical Cancer Research
1 reference
stated in
Europe PubMed Central
PMCID
3990645
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24583800%20AND%20SRC:MED&resulttype=core&format=json
retrieved
9 March 2020
volume
20
1 reference
stated in
Europe PubMed Central
PMCID
3990645
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24583800%20AND%20SRC:MED&resulttype=core&format=json
retrieved
9 March 2020
issue
8
1 reference
stated in
Europe PubMed Central
PMCID
3990645
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24583800%20AND%20SRC:MED&resulttype=core&format=json
retrieved
9 March 2020
page(s)
2051-2059
1 reference
stated in
Europe PubMed Central
PMCID
3990645
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24583800%20AND%20SRC:MED&resulttype=core&format=json
retrieved
9 March 2020
cites work
Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3990645
retrieved
23 August 2017
Somatic mutations of calreticulin in myeloproliferative neoplasms
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3990645
retrieved
23 August 2017
Phase II trial of panobinostat, an oral pan-deacetylase inhibitor in patients with primary myelofibrosis, post-essential thrombocythaemia, and post-polycythaemia vera myelofibrosis
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3990645
retrieved
23 August 2017
Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3990645
retrieved
23 August 2017
Intrinsic resistance to JAK2 inhibition in myelofibrosis
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3990645
retrieved
23 August 2017
Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3990645
retrieved
23 August 2017
Crystal structures of the JAK2 pseudokinase domain and the pathogenic mutant V617F
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3990645
retrieved
23 August 2017
Modulation of Activation-Loop Phosphorylation by JAK Inhibitors Is Binding Mode Dependent
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3990645
retrieved
23 August 2017
Somatic STAT3 mutations in large granular lymphocytic leukemia
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3990645
retrieved
23 August 2017
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3990645
retrieved
23 August 2017
JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3990645
retrieved
23 August 2017
Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3990645
retrieved
23 August 2017
Essential role for Stat5a/b in myeloproliferative neoplasms induced by BCR-ABL1 and JAK2(V617F) in mice.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3990645
retrieved
23 August 2017
The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3990645
retrieved
23 August 2017
Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3990645
retrieved
23 August 2017
Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550).
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3990645
retrieved
23 August 2017
Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3990645
retrieved
23 August 2017
Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3990645
retrieved
23 August 2017
Recombinant human erythropoietin antagonizes trastuzumab treatment of breast cancer cells via Jak2-mediated Src activation and PTEN inactivation
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3990645
retrieved
23 August 2017
HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3990645
retrieved
23 August 2017
MiR-375 frequently downregulated in gastric cancer inhibits cell proliferation by targeting JAK2.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3990645
retrieved
23 August 2017
JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3990645
retrieved
23 August 2017
Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3990645
retrieved
23 August 2017
JAK mutations in high-risk childhood acute lymphoblastic leukemia
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3990645
retrieved
23 August 2017
JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3990645
retrieved
23 August 2017
JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3990645
retrieved
23 August 2017
MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3990645
retrieved
23 August 2017
JAK2T875N is a novel activating mutation that results in myeloproliferative disease with features of megakaryoblastic leukemia in a murine bone marrow transplantation model
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3990645
retrieved
23 August 2017
Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3990645
retrieved
23 August 2017
Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3990645
retrieved
23 August 2017
The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3990645
retrieved
23 August 2017
A gain-of-function mutation of JAK2 in myeloproliferative disorders
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3990645
retrieved
23 August 2017
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3990645
retrieved
23 August 2017
The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3990645
retrieved
23 August 2017
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3990645
retrieved
23 August 2017
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3990645
retrieved
23 August 2017
Lnk inhibits erythropoiesis and Epo-dependent JAK2 activation and downstream signaling pathways
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3990645
retrieved
23 August 2017
Jak3 and the pathogenesis of severe combined immunodeficiency
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3990645
retrieved
23 August 2017
Some speculations on the myeloproliferative syndromes.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3990645
retrieved
23 August 2017
Partial impairment of cytokine responses in Tyk2-deficient mice
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3990645
retrieved
23 August 2017
Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3990645
retrieved
23 August 2017
Jak2 is essential for signaling through a variety of cytokine receptors
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3990645
retrieved
23 August 2017
Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3990645
retrieved
23 August 2017
A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3990645
retrieved
23 August 2017
Dual PI3K/AKT/mTOR inhibitor BEZ235 synergistically enhances the activity of JAK2 inhibitor against cultured and primary human myeloproliferative neoplasm cells
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3990645
retrieved
6 September 2017
Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3990645
retrieved
6 September 2017
Janus kinase 3-activating mutations identified in natural killer/T-cell lymphoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3990645
retrieved
6 September 2017
JAK2V617F-mediated phosphorylation of PRMT5 downregulates its methyltransferase activity and promotes myeloproliferation
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3990645
retrieved
14 September 2017
Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3990645
retrieved
14 September 2017
SOCS-mediated downregulation of mutant Jak2 (V617F, T875N and K539L) counteracts cytokine-independent signaling
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3990645
retrieved
14 September 2017
Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3990645
retrieved
14 September 2017
Activating alleles of JAK3 in acute megakaryoblastic leukemia
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3990645
retrieved
14 September 2017
Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3990645
retrieved
28 September 2017
Crystal structure of the Jak3 kinase domain in complex with a staurosporine analog
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3990645
retrieved
23 June 2018
The cell cycle regulator CDC25A is a target for JAK2V617F oncogene.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3990645
retrieved
1 September 2018
Akt activation through the phosphorylation of erythropoietin receptor at tyrosine 479 is required for myeloproliferative disorder-associated JAK2 V617F mutant-induced cellular transformation.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3990645
retrieved
1 September 2018
Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3990645
retrieved
1 September 2018
Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3990645
retrieved
1 September 2018
The V617F mutation in Jak2 is not found in childhood acute lymphoblastic leukaemia.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3990645
retrieved
1 September 2018
STAT3 is constitutively active in some patients with Polycythemia rubra vera
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3990645
retrieved
1 September 2018
Stat5 is essential for the myelo- and lymphoproliferative disease induced by TEL/JAK2
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3990645
retrieved
2 October 2018
Genomic imbalances including amplification of the tyrosine kinase gene JAK2 in CD30+ Hodgkin cells
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/24583800
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Mutational screen reveals a novel JAK2 mutation, L611S, in a child with acute lymphoblastic leukemia
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/24583800
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Identifiers
DOI
10.1158/1078-0432.CCR-13-0279
1 reference
stated in
Europe PubMed Central
PMCID
3990645
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24583800%20AND%20SRC:MED&resulttype=core&format=json
retrieved
9 March 2020
PMCID
3990645
1 reference
stated in
Europe PubMed Central
PMCID
3990645
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24583800%20AND%20SRC:MED&resulttype=core&format=json
retrieved
9 March 2020
PubMed ID
24583800
1 reference
stated in
Europe PubMed Central
PMCID
3990645
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24583800%20AND%20SRC:MED&resulttype=core&format=json
retrieved
9 March 2020
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit
